Diana (Dogaru) Barb MD
Diabetes, Lipid Metabolism, Thyroid
Assistant Professor, Medicine, U of FL Coll of Med
Join to View Full Profile
1601 SW Archer RdGainesville, FL 32608
Phone+1 352-376-1611
Fax+1 352-627-4268
Dr. Barb is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Emory University School of MedicineFellowship, Endocrinology, Diabetes, and Metabolism, 2011 - 2013- Emory University School of MedicineResidency, Internal Medicine, 2008 - 2011
University of Tirgu-Mures Faculty of MedicineClass of 1999
Certifications & Licensure
FL State Medical License 2013 - 2027
GA State Medical License Active through 2013
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
American Board of Obesity Medicine Obesity Medicine
ABOMABOM
Clinical Trials
- Skeletal Muscle Inflammation, Oxidative Stress and DNA Repair in Age-Related Sarcopenia Start of enrollment: 2014 May 01
- Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease Start of enrollment: 2018 Aug 14
Roles: Contact, Sub-Investigator
Publications & Presentations
PubMed
- 3 citationsPan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD.Diana Barb, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, Fernando Bril, Philippe Huot-Marchand
Journal of Hepatology. 2025-01-15 - 1 citationsObesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screen.Anu Sharma, Eddison Godina Leiva, Srilaxmi Kalavalapalli, Romina Lomonaco, Stephen A Marangi
Obesity. 2024-10-01 - 12 citationsThe Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.Layla A Abushamat, Pir Ahmad Shah, Robert H Eckel, Stephen A Harrison, Diana Barb
Clinical Gastroenterology and Hepatology. 2024-08-01
Journal Articles
- Effect of Canagliflozin Treatment on Hepatic Triglyceride Content and Glucose Metabolism in Patients with Type 2 DiabetesDiana Barb, Sunder Mudaliar, Kenneth Cusi, Diabetes, Obesity and Metabolism
Press Mentions
UF Health Screening Patients in What Might Be Largest Fatty Liver Study of Its Kind in the U.S.December 21st, 2020
UF Health Researchers Study Association Between Type 2 Diabetes and Fatty Liver DiseaseNovember 20th, 2018
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
